A Phase 4 interventional study of Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution in Cataract, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-07.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing moxifloxacin in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Moxifloxacin · Cataract.
Among the 12 studies testing moxifloxacin in Cataract, this one is the 10th largest by enrollment, is the only one that started in 2012, is one of 9 in phase 4, and was the 8th registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →1 of the 12 studies testing moxifloxacin in Cataract is open now, in 1 country. Recruiting first, the newest first:
Laboratorios Sophia S.A de C.V. · Sites in Mexico
Ages 18+
By country, each count listing its studies:
Moxifloxacin: first FDA approval 1999 (AVELOX). What it is approved for, and how studies give it, is on its page →
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 62 across the 12 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 9 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
116 studies in Cataract by Alcon: 4 open now, 6 under way, none of them phase 3. Of 101 finished, 76 (75%) have results posted.
Among the 116 studies in Cataract by Alcon, this one is the 81st largest by enrollment of the 104 interventional ones that give a count, is one of 6 that started in 2012, is one of 23 in phase 4, and was the 65th registered.
Alcon’s Cataract studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing moxifloxacin in Cataract, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 116 in Cataract:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine the moxifloxacin aqueous penetration when dosing with a combination drug Vigadexa preoperatively in cataract patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution, 1 drop instilled in the study eye 2 days before surgery, followed by 1 drop instilled 4 times a day the day before surgery. On the day of surgery, 1 drop was instilled 60 minutes prior to the procedure.
Drug: Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
Drug page: Moxifloxacin
Also known as: Vigadexa®
Mean Aqueous Humor Concentration of Moxifloxacin
A 0.150 milliliter sample of the aqueous humor was obtained during cataract surgery. The concentration of moxifloxacin was measured by a validated procedure using high performance liquid-spectrometry.
Time frame: Day 3 (operative day)
Subjects were recruited from one study center in Brazil.
| Milestone | VIGADEXA |
|---|---|
| Started | 36 |
| Completed | 31 |
| Not completed | 5 |
| Withdrew: Protocol deviation | 3 |
| Withdrew: Adverse event | 2 |
A 0.150 milliliter sample of the aqueous humor was obtained during cataract surgery. The concentration of moxifloxacin was measured by a validated procedure using high performance liquid-spectrometry.
| nanograms per milliliter | VIGADEXA |
|---|---|
| Mean Aqueous Humor Concentration of Moxifloxacin | 1110.6 (857.5 to 1363.7) |
Collected over Adverse events were collected for the duration of the study. An adverse event was defined as any untoward medical occurrence, or deterioration of a pre-existing medical condition, that occurred during or after test product administration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VIGADEXA | — | 0/36 (0%) | 2/36 (5.6%) |
| Event | VIGADEXA |
|---|---|
| Hypertensive CrisisCardiac disorders | 2/36 |
This reporting group includes all enrolled subjects who received all doses of the test product.
| Age Continuous(years) | VIGADEXA |
|---|---|
| Mean | 71.2 ± 10.4 |
| Sex: Female, Male(Participants) | VIGADEXA |
|---|---|
| Female | 21 |
| Male | 14 |
No study locations are listed for this record.
The record gives a start of Apr 2012, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin